Dysregulation of the CDK9–CCNT1complex drives pathological transcription in cancers, fueling tumorprogression, metastasis, and therapy resistance. To target this interaction, the iridium­(III) complex 8 was designed with 7-chloro-2-phenylquinoline C∧N ligands and a 2,2′-bipyridine N∧N ligand,leveraging metal coordination to disrupt the CDK9–CCNT1 PPI(Figure C). Here, CDK9 is linked to cancer.